Barrett's endoscopic therapy is the modern standard of care for Barrett's esophagus that has progressed to dysplasia (precancerous change) or early-stage esophageal adenocarcinoma confined to the mucosa (Rubenstein et al., AGA Guideline, Gastroenterology, 2024; Shaheen et al., ACG Guideline, 2022). The core principle is simple and powerful: remove any visible or raised lesion by endoscopic resection — which also provides the tissue needed for accurate staging — and then ablate the remaining flat Barrett's segment so the entire at-risk lining is eliminated and replaced by healthy squamous tissue (Shah et al., Nature Reviews Clinical Oncology, 2023; NCCN Esophageal Guideline, 2026).

This approach has transformed care over the past two decades. Before it existed, high-grade dysplasia and early cancer were often treated with esophagectomy — removal of the esophagus — a major operation with real mortality and lifelong consequences. Because the risk of lymph node spread in high-grade dysplasia and intramucosal (T1a) cancer is very low, endoscopic therapy now achieves comparable oncologic outcomes without any incisions, reserving surgery for deeper or higher-risk disease (Molena et al., AATS Consensus, 2025; NCCN Esophageal Guideline, 2026).

The evidence base is strong. In the landmark AIM Dysplasia randomized trial, RFA completely eradicated dysplasia in 90.5% of patients with low-grade dysplasia and 81% with high-grade dysplasia, eliminated intestinal metaplasia in 77%, and cut progression to cancer at one year from 9.3% to 1.2% (Spechler, Wang & Souza, Yamada's Textbook of Gastroenterology, 2022; Shah et al., Nature Reviews Clinical Oncology, 2023). Long-term registry data confirm durability, with a 10-year cancer rate of about 4.1% and most relapses occurring early and retreatable endoscopically (Wolfson et al., Gastrointestinal Endoscopy, 2022).

‍

Barrett's endoscopic therapy works by physically eliminating the abnormal, genetically unstable lining that carries cancer risk, and allowing the esophagus to heal with normal squamous epithelium in its place (Fitzgerald, New England Journal of Medicine, 2026). It uses two complementary techniques:

• Endoscopic resection (EMR or ESD) removes any visible nodule, lump, or focal lesion. This is both therapeutic and diagnostic — the resected specimen is examined by a pathologist to confirm the exact depth of invasion and grade, information that is more accurate than biopsy or ultrasound and that determines whether endoscopic therapy alone is sufficient (Fitzgerald, New England Journal of Medicine, 2026; Molena et al., AATS Consensus, 2025).

• Ablation (most often radiofrequency ablation) then destroys the remaining flat Barrett's tissue using precisely controlled thermal energy that creates a uniform, shallow burn — deep enough to remove the metaplastic lining but shallow enough to limit injury to the esophageal wall (Spechler, Wang & Souza, Yamada's Textbook of Gastroenterology, 2022).

The combination matters: resection alone leaves residual Barrett's that carries a 20–35% risk of recurrent neoplasia, so ablating the rest is essential to a durable, curative result (Molena et al., AATS Consensus, 2025).

‍

• Avoids major surgery — spares patients the morbidity and mortality of esophagectomy while achieving comparable cancer control for high-grade dysplasia and intramucosal cancer (Molena et al., AATS Consensus, 2025; NCCN Esophageal Guideline, 2026).

• Highly effective — eradicates dysplasia in roughly 80–90% of patients and dramatically reduces progression to cancer (Shaheen et al., New England Journal of Medicine, 2009; Sharma, JAMA, 2022).

• Incisionless and outpatient — performed entirely through the endoscope, with no external incisions and same-day discharge in most cases.

• Preserves the esophagus — patients keep normal swallowing and digestion.

• Accurate staging — endoscopic resection upgrades the pathologic diagnosis in up to 40% of cases, ensuring the right treatment decision (Al-Haddad et al., ASGE Guideline, 2023).

• Prevents cancer — in confirmed low-grade dysplasia, RFA reduced progression to high-grade dysplasia or cancer from 26.5% to 1.5% over three years in the SURF trial (Elias & Spechler, The Esophagus, 2021).

• Repeatable — recurrences are usually caught early on surveillance and successfully re-treated endoscopically (Wolfson et al., Gastrointestinal Endoscopy, 2022).

‍

Barrett's endoscopic therapy is indicated for patients with biopsy-confirmed neoplasia along the Barrett's spectrum:

• High-grade dysplasia — endoscopic eradication therapy is the standard of care (Shaheen et al., ACG Guideline, 2022).

• Confirmed low-grade dysplasia — endoscopic eradication therapy is offered as an alternative to close surveillance, after expert pathology confirmation (Wani et al., AGA Clinical Practice Update, 2016; Barret et al., Gut, 2021).

• Intramucosal (T1a) adenocarcinoma — appropriate when the lesion is well or moderately differentiated, without lymphovascular invasion, because lymph node risk is low (NCCN Esophageal Guideline, 2026; Molena et al., AATS Consensus, 2025).

• Selected superficial T1b cancer — considered in low-risk lesions after thorough multidisciplinary review (NCCN Esophageal Guideline, 2026).

Two groups are generally not candidates for ablation: patients with non-dysplastic Barrett's esophagus, in whom the low cancer risk does not justify the stricture risk of RFA (surveillance is preferred), and patients with deeper (SM2/SM3) or high-risk cancer, who warrant surgical and oncologic evaluation (Fitzgerald, New England Journal of Medicine, 2026; NCCN Esophageal Guideline, 2026). A critical prerequisite is that any dysplasia diagnosis be confirmed by a pathologist with gastrointestinal expertise before treatment (Shaheen et al., ACG Guideline, 2022).

‍

The therapy is typically delivered over several sessions spaced about 2–3 months apart, continuing until the Barrett's segment is completely eradicated (Barret et al., Gut, 2021). Each session is performed under sedation or anesthesia as a day procedure:

1. High-resolution inspection — the Barrett's segment is examined with high-definition white-light endoscopy and virtual chromoendoscopy, often with a clear cap, to map its extent (Prague C & M) and identify any visible lesions (Shaheen et al., ACG Guideline, 2022).

1. Resection of visible lesions first — any nodule or focal lesion is removed by EMR (commonly band-ligation multiband mucosectomy) or, for larger or deeper-appearing lesions, ESD (Sharma, JAMA, 2022).

1. Pathologic staging — the resected specimen is reviewed to confirm depth, grade, margins, and lymphovascular status before proceeding (Molena et al., AATS Consensus, 2025).

1. Ablation of residual flat Barrett's — RFA is applied, using a circumferential balloon catheter for long segments and a focal device for smaller areas or touch-ups; cryotherapy or hybrid argon plasma coagulation are alternatives (Spechler, Wang & Souza, Yamada's Textbook of Gastroenterology, 2022; Shah et al., Nature Reviews Clinical Oncology, 2023).

1. Repeat sessions until complete eradication of dysplasia and intestinal metaplasia is confirmed on biopsies at two consecutive endoscopies (Wolfson et al., Gastrointestinal Endoscopy, 2022).

EMR vs. ESD — EMR remains first-line for most lesions ≤20 mm, while ESD is favored for lesions larger than about 15 mm, those with a bulky component, or any lesion suspicious for deeper submucosal invasion, because ESD achieves higher en-bloc and R0 (margin-negative) resection rates (Al-Haddad et al., ASGE Guideline, 2023; Fujiyoshi et al., Gastrointestinal Endoscopy, 2024). For early T1a disease, complete remission rates are similar between the two, so EMR's speed and lower cost often make it the practical choice (Terheggen et al., Gut, 2017).

‍

Barrett's endoscopic therapy is safe, but it carries procedure-specific risks:

• Esophageal stricture — the most common complication, occurring in roughly 6–10% of patients and usually managed with endoscopic dilation; strictures are more frequent when RFA is combined with EMR (Sharma, JAMA, 2022; Spechler, Wang & Souza, Yamada's Textbook of Gastroenterology, 2022).

• Bleeding — about 1% (Sharma, JAMA, 2022).

• Perforation — rare, approximately 0.2% (Sharma, JAMA, 2022).

• Post-procedure chest pain and transient difficulty swallowing — common after RFA and generally self-limited; newer modalities such as hybrid argon plasma coagulation may cause less pain and fewer strictures with comparable eradication (Klimkowski et al., Gastrointestinal Endoscopy, 2026).

• Incomplete eradication or need for additional sessions — more likely with longer segments, large hiatal hernia, or prior incomplete treatment (Goyal et al., Gastrointestinal Endoscopy, 2026).

Overall adverse-event rates are higher when RFA is combined with EMR (about 22%) than with RFA alone (about 5%) (Sharma, JAMA, 2022).

‍

Recovery is quick. Most patients go home the same day and resume normal activities within 24–48 hours. A soft or liquid diet is typically advised for a few days after each session while the treated area heals, and acid-suppression medication is intensified during healing (Fitzgerald, New England Journal of Medicine, 2026). Temporary chest discomfort, a sensation of food sticking, or mild swallowing difficulty for several days is expected and usually resolves on its own (Klimkowski et al., Gastrointestinal Endoscopy, 2026). Because the esophagus itself is not cut or rerouted, there is no major operative recovery period between or after sessions.

‍

Once complete eradication of intestinal metaplasia (CE-IM) is achieved, the long-term outlook is excellent. Across large series, endoscopic therapy eliminates dysplasia in about 80–90% of patients, and the subsequent cancer risk is low — a pooled esophageal adenocarcinoma incidence of roughly 2.2 per 1,000 person-years after CE-IM (Alsaleh et al., Gastrointestinal Endoscopy, 2026; Wolfson et al., Gastrointestinal Endoscopy, 2022).

Recurrence of intestinal metaplasia does occur — reported anywhere from 5% to nearly 40%, pooled at about 7.5 per 100 patient-years, with dysplasia recurrence around 1.7 per 100 patient-years — which is why lifelong surveillance remains essential (Komanduri, Muthusamy & Wani, Gastroenterology, 2018; Wani et al., AGA Clinical Practice Update, 2016). Most recurrences appear within the first 1–2 years, cluster at the esophagogastric junction, and are successfully re-treated endoscopically (Rubenstein et al., AGA Guideline, 2024). Durability is strongly improved by aggressive reflux control after eradication (Komanduri, Muthusamy & Wani, Gastroenterology, 2018).

‍

Barrett's esophagus and its treatment sit squarely at the intersection of Dr. de la Cruz-Muñoz's expertise as a fellowship-trained, board-certified metabolic and foregut surgeon. The two factors that most powerfully drive Barrett's — chronic reflux and obesity — are precisely what his practice is built to address, and weight loss itself is associated with roughly a 31% lower risk of esophageal adenocarcinoma (Xie, Smyth & Lagergren, New England Journal of Medicine, 2026). He provides comprehensive foregut evaluation, coordinates expert gastrointestinal pathology review of any dysplasia, and ensures each patient is matched to the correct level of care — surveillance, endoscopic eradication therapy, antireflux or weight-loss surgery, or multidisciplinary oncologic management for higher-risk disease. Because outcomes and durability depend heavily on experience and on rigorous post-treatment reflux control and surveillance, patients benefit from a program that manages the entire reflux-to-cancer continuum under one roof rather than in fragments.

‍

Not applicable — Barrett's endoscopic therapy is an esophageal cancer-prevention procedure, not a weight-loss operation, and does not produce or target weight loss. For patients whose Barrett's is driven in part by obesity, weight loss is pursued separately (through medical therapy or bariatric surgery) and is associated with reduced esophageal adenocarcinoma risk (Xie, Smyth & Lagergren, New England Journal of Medicine, 2026).

‍

Not a metabolic procedure. The "improvement" this therapy delivers is oncologic: eradication of precancerous tissue and a markedly reduced risk of progression to esophageal cancer (Shaheen et al., New England Journal of Medicine, 2009). Any metabolic benefit comes only from accompanying weight management, not from the ablation or resection itself.

‍

Not applicable to this procedure. The analogous concept here is recurrence prevention: the most important strategy to keep Barrett's from returning after eradication is strict, durable reflux control (daily proton pump inhibitor therapy, and antireflux surgery when appropriate), combined with structured endoscopic surveillance (Komanduri, Muthusamy & Wani, Gastroenterology, 2018; Fitzgerald, New England Journal of Medicine, 2026).

‍

Reflux control is central to this procedure's success, not incidental to it. Chronic acid and bile reflux cause Barrett's in the first place, and ongoing reflux after eradication is a leading driver of recurrence; aggressive acid suppression after CE-IM has been associated with dramatically lower recurrence rates (Komanduri, Muthusamy & Wani, Gastroenterology, 2018). All patients are maintained on proton pump inhibitor therapy during and after treatment to promote healing and durability, and antireflux surgery is a good option for patients with inadequate symptom control or intolerable medication side effects (Fitzgerald, New England Journal of Medicine, 2026). Controlling reflux does not by itself reverse the Barrett's lining, but it is essential for improving quality of life, reducing stricture risk, and protecting the eradication result (Fitzgerald, New England Journal of Medicine, 2026).

‍

If eradication is incomplete or Barrett's recurs, options include additional RFA or focal ablation sessions, repeat endoscopic resection (EMR or ESD) of any new visible lesion, and alternative ablation modalities such as cryotherapy or hybrid argon plasma coagulation (Shah et al., Nature Reviews Clinical Oncology, 2023; Klimkowski et al., Gastrointestinal Endoscopy, 2026). Patients who did not achieve complete eradication after community RFA frequently succeed when managed at an experienced multidisciplinary center (Goyal et al., Gastrointestinal Endoscopy, 2026). If pathology from resection reveals deeper or high-risk invasive cancer, treatment escalates to surgical (esophagectomy) and/or oncologic therapy (NCCN Esophageal Guideline, 2026).

‍

Not applicable — this endoscopic procedure does not affect body composition, lean mass, or nutrition in the way bariatric surgery does, because the gastrointestinal tract is not rerouted and absorption is unchanged. Patients maintain normal eating and nutrition apart from brief dietary modification during healing after each session.

‍

Endoscopic eradication therapy for dysplastic Barrett's esophagus and early esophageal cancer is a guideline-endorsed standard of care and is generally covered when medically indicated, but requirements vary by payer. Typical documentation includes endoscopy and biopsy confirming Barrett's esophagus with dysplasia or early cancer, expert/second-pathologist confirmation of the dysplasia grade, and the Prague C & M extent (Shaheen et al., ACG Guideline, 2022). Coverage, prior authorization, and session limits differ among plans; our office verifies benefits and obtains authorization before treatment.

‍

Confirmatory pathology — dysplasia confirmed by a gastrointestinal pathologist before any ablation (Shaheen et al., ACG Guideline, 2022).

High-definition mapping endoscopy with chromoendoscopy and Seattle-protocol biopsies to define extent and exclude an unrecognized lesion (Shaheen et al., ACG Guideline, 2022).

Optimized acid suppression — intensified PPI therapy before treatment to heal inflammation and improve the quality of ablation (Fitzgerald, New England Journal of Medicine, 2026).

Medication review — anticoagulant and antiplatelet management planned in advance, as resection and ablation carry bleeding risk.

Fasting and anesthesia planning per standard endoscopy protocols.

‍

A liquid-to-soft diet is generally recommended for several days after each session, advancing back to a normal diet as the treated area heals (Fitzgerald, New England Journal of Medicine, 2026). Adequate hydration and acid suppression support healing. Unlike bariatric surgery, there are no lifelong dietary restrictions or supplement requirements, because digestion and absorption are unaffected.

‍

Most patients resume normal activity within a day or two of each outpatient session. Strenuous activity is typically deferred only briefly, and there are no long-term activity restrictions. Patients are counseled on the broader lifestyle measures that reduce Barrett's and cancer risk across the continuum — weight management, tobacco cessation, and reflux-reducing habits (Wani et al., AGA Guideline, 2025).

‍